

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Lixisenatide (Lyxumia®)	
Indication under review	Treatment of type 2 Diabetes Mellitus	
Policy No:	APC 002	
Date of Issue/Date of re-issue:	May 2013, May 2015	
Review Date:	May 2018	
Policy Statement: Lixisenatide (Lyxumia®) is recommended as an option for use in combination with basal insulin or oral antidiabetic drugs for treating patients with type 2 diabetes.		
Traffic Light Status	Green	
Key Points considered:		
<ul style="list-style-type: none"> • HbA_{1c} reductions were 0.5-0.9 percentage points greater than that seen with placebo. • A once daily GLP-1 mimetic which costs 15% less than Byetta® and 26% less than Victoza® • This treatment may be considered as the first line GLP-1 mimetic. 		
References:		
Report compiled from NICE Evidence Summary New Medicines (ESNM) 10 Available at http://publications.nice.org.uk/esnm10-type-2-diabetes-lixisenatide-esnm10/about-this-evidence-summary-2 Key evidence from Fonseca VA, Alvarado-Ruiz R, Raccach D et al. (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy. <i>Diabetes Care</i> 35: 1225–31 Seino Y, Min KW, Niemoeller E et al. (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2		
Date taken to APC:	1 st May 2013	
Date Ratified by MMC on Behalf of the Board:	10 th July 2013	
Expired policy reviewed by APC	6 th May 2015	
Date ratified by GP MOC	17 th June 2015	